[Federal Register Volume 72, Number 215 (Wednesday, November 7, 2007)]
[Notices]
[Pages 62867-62868]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-5554]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--SAE Consortium Ltd.

    Notice is hereby given that, on September 27, 2007, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), SAE Consortium Ltd. 
(``SAEC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: Abbott Laboratories, Abbott Park, IL; F. Hoffmann-
La Roche, Inc., Basel, SWITZERLAND; Johnson & Johnson Pharmaceutical 
Research & Development, LLC, Raritan, NJ; Pfizer, Inc., New York, NY; 
Sanofi-Aventis, Bridgewater, NJ; SmithKline Beecham Corporation d/b/a 
GlaxoSmithKline, Research Triangle Park, NC; and Wyeth Pharmaceuticals 
Inc., Collegeville, PA. The SAEC's general area of planned activities 
is to carry out scientific research in the public interest, including 
research directed toward the discovery of DNA-variants that are 
clinically useful in understanding and predicting the risk of drug 
induced serious adverse events and similar scientific research, the 
results of which

[[Page 62868]]

will then be made freely available to the public on a nondiscriminatory 
basis. The venture will enable SAEC to identify DNA-variants useful in 
understanding and predicting the risk of drug induced serious adverse 
events with shared financial risk and without the duplication of effort 
that would result from the work of individual members. As the research 
results are gathered, they will be placed in the public domain for use 
by the worldwide medical research community in identifying specific 
genes involved in causing serious adverse events, thereby facilitating 
downstream research and development of therapeutic diagnostic and 
pharmaceutical products.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. 07-5554 Filed 11-06-07; 8:45 am]
BILLING CODE 4410-11-M